Top of page

Corporate

Practice

Filters

CureVac $245.3 million IPO

Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which…

CureVac $245.3 million IPO

Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which…

CureVac $245.3 million IPO

Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which…

CureVac $245.3 million IPO

Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which…

Visa $3.25 billion notes offering

Davis Polk advised Visa Inc. on its SEC-registered offering of $500 million of 0.750% senior notes due 2027, $1 billion of 1…
Back to top